Veracyte Stock Performance
| VCYT Stock | USD 41.10 1.51 3.81% |
On a scale of 0 to 100, Veracyte holds a performance score of 12. The entity has a beta of 1.36, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Veracyte will likely underperform. Please check Veracyte's sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether Veracyte's existing price patterns will revert.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Veracyte are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Veracyte unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.53 | Five Day Return 7.01 | Year To Date Return 53.8 | Ten Year Return 534.64 | All Time Return 218.04 |
1 | Insider Trading | 09/03/2024 |
2 | Should You Continue to Retain ABT Stock in Your Portfolio Now | 09/05/2024 |
3 | Disposition of 1965 shares by Jones Evan Fa of Veracyte at 30.3217 subject to Rule 16b-3 | 09/11/2024 |
4 | Disposition of 5173 shares by Jones Evan Fa of Veracyte at 35.2335 subject to Rule 16b-3 | 09/19/2024 |
5 | Acquisition by Bhanji Muna of 11473 shares of Veracyte subject to Rule 16b-3 | 09/26/2024 |
6 | Paragon 28, Inc. Stock Jumps 7.2 percent Will It Continue to Soar | 10/30/2024 |
7 | Veracyte Inc Q3 2024 Earnings Call Highlights Record Revenue Growth and Strategic Outlook | 11/07/2024 |
8 | Veracyte Posts Quarterly Earnings Results, Beats Expectations By 0.17 EPS | 11/08/2024 |
9 | Veracyte, Inc. Is About To Turn The Corner | 11/12/2024 |
10 | Veracyte CFO Rebecca Chambers sells 585,663 in company stock | 11/14/2024 |
11 | Wolfe Research sets stock target on Veracyte, cites growth potential | 11/15/2024 |
12 | Disposition of 10125 shares by Eastham Karin of Veracyte at 38.756 subject to Rule 16b-3 | 11/19/2024 |
13 | Insider Sell Alert Karin Eastham Sells 14,731 Shares of Veracyte Inc | 11/22/2024 |
| Begin Period Cash Flow | 155 M |
Veracyte |
Veracyte Relative Risk vs. Return Landscape
If you would invest 3,162 in Veracyte on August 28, 2024 and sell it today you would earn a total of 948.00 from holding Veracyte or generate 29.98% return on investment over 90 days. Veracyte is currently generating 0.455% in daily expected returns and assumes 2.7854% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Veracyte, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Veracyte Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Veracyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Veracyte, and traders can use it to determine the average amount a Veracyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1633
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VCYT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.79 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.46 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Veracyte is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Veracyte by adding it to a well-diversified portfolio.
Veracyte Fundamentals Growth
Veracyte Stock prices reflect investors' perceptions of the future prospects and financial health of Veracyte, and Veracyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Veracyte Stock performance.
| Return On Equity | -0.0083 | ||||
| Return On Asset | 0.0107 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 2.93 B | ||||
| Shares Outstanding | 77.5 M | ||||
| Price To Earning | (10.61) X | ||||
| Price To Book | 2.61 X | ||||
| Price To Sales | 7.49 X | ||||
| Revenue | 361.05 M | ||||
| Gross Profit | 194.95 M | ||||
| EBITDA | (49.41 M) | ||||
| Net Income | (74.4 M) | ||||
| Cash And Equivalents | 170.11 M | ||||
| Cash Per Share | 2.37 X | ||||
| Total Debt | 12.63 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.09 X | ||||
| Book Value Per Share | 15.18 X | ||||
| Cash Flow From Operations | 44.22 M | ||||
| Earnings Per Share | (0.13) X | ||||
| Market Capitalization | 3.19 B | ||||
| Total Asset | 1.11 B | ||||
| Retained Earnings | (468.12 M) | ||||
| Working Capital | 224.38 M | ||||
| Current Asset | 47.91 M | ||||
| Current Liabilities | 14.72 M | ||||
About Veracyte Performance
Assessing Veracyte's fundamental ratios provides investors with valuable insights into Veracyte's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Veracyte is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 52.14 | 61.67 | |
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.08) | (0.09) | |
| Return On Assets | (0.07) | (0.07) | |
| Return On Equity | (0.07) | (0.07) |
Things to note about Veracyte performance evaluation
Checking the ongoing alerts about Veracyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Veracyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 361.05 M. Net Loss for the year was (74.4 M) with profit before overhead, payroll, taxes, and interest of 194.95 M. | |
| Over 99.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Insider Sell Alert Karin Eastham Sells 14,731 Shares of Veracyte Inc |
- Analyzing Veracyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Veracyte's stock is overvalued or undervalued compared to its peers.
- Examining Veracyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Veracyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Veracyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Veracyte's stock. These opinions can provide insight into Veracyte's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.